Frankfurt
08.10.26 | 08:01
0,012 Euro
-0,85 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ACARIX Aktie jetzt für 0€ handeln | |||||
| 14:15 | Acarix AB: Acarix Provides Update on RHTP and Saudi Arabia Regulatory Process | 79 | GlobeNewswire (Europe) | Acarix has received several inquiries from shareholders regarding the status of the U.S. Rural Health Transformation Program (RHTP) and regulatory approval in the Kingdom of Saudi Arabia (KSA) and would... ► Artikel lesen | |
| 11.09. | Acarix AB: Peer-Reviewed Study Confirms CADScor System Can Diagnose Heart Failure With Far Fewer False Positives Than Standard Blood Test | 360 | GlobeNewswire (Europe) | Aalborg University-led research, published in PLOS Digital Health, found the CADScor System's acoustic sensing platform identified heart failure with diagnostic accuracy comparable to a leading blood... ► Artikel lesen | |
| 13.08. | Acarix AB Q2 Sales Increase | 10 | RTTNews | ||
| 13.08. | Earnings Call: Acarix meldet starkes Wachstum für Q2 2026, doch die Aktie gibt nach | 10 | Investing.com Deutsch | ||
| 13.08. | Acarix Q2 2026 slides: US revenue surges 212%, losses narrow | 5 | Investing.com | ||
| 13.08. | Acarix Q2 2026 slides: revenue doubles as US growth accelerates | 1 | Investing.com | ||
| 13.08. | Acarix AB: Acarix Publishes Second Quarter and First Half 2026 Results | 205 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its interim financial results for the second quarter and first half 2026. The report highlights continued commercial... ► Artikel lesen | |
| 17.06. | Acarix AB: Announcement from the annual general meeting in Acarix AB | 304 | GlobeNewswire (Europe) | The annual general meeting 2026 (the "AGM") of Acarix AB ("Acarix" or the "Company") was held today on 17 June 2026 and the following resolutions were passed by the meeting.
Adoption of the income statement... ► Artikel lesen | |
| 18.05. | Earnings Call: Acarix verzeichnet starkes US-Wachstum im ersten Quartal 2026 | 2 | Investing.com Deutsch | ||
| 18.05. | Acarix AB: Acarix Publishes Interim Report, January - March 2026 | 327 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its interim financial results for the first quarter of 2026. The report highlights meaningful progress across the... ► Artikel lesen | |
| 12.02. | Acarix AB: Acarix Publishes Year-End Report 2025 | 315 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its 2025 year-end financial results. "Last year was a year of meaningful commercial and operational... ► Artikel lesen | |
| 11.02. | Acarix AB: Acarix Announces New Distribution Partner in Saudi Arabia for the CADScor System | 498 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix AB (Nasdaq Stockholm: ACARIX), a medical device company advancing noninvasive, AI enabled diagnostics for coronary artery disease, today announced that it has entered into a strategic... ► Artikel lesen | |
| 04.02. | Acarix AB: Acarix Receives EU MDR Certification for the CADScorSystem | 417 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announced that its CADScor System has successfully achieved certification under the European Union Medical... ► Artikel lesen | |
| 06.11.25 | Acarix AB: Acarix Publishes Interim Report, Third quarter 2025 | 303 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the third quarter of 2025. The report highlights international... ► Artikel lesen | |
| 27.10.25 | Acarix AB: Announcement from the general meeting in Acarix AB | 358 | GlobeNewswire (Europe) | The extraordinary general meeting 2025 (the "EGM") of Acarix AB ("Acarix" or the "Company") was held today on 27 October 2025 and the following resolutions were passed unanimously by the meeting.
Change... ► Artikel lesen | |
| 17.10.25 | Acarix AB: Acarix responds to G-BA decision on reimbursement in the German market | 401 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announce that G-BA reached a negative decision on the possibility for CADScor System to receive reimbursement... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 36,450 | -2,59 % | EQS-Adhoc: Fresenius Medical Care AG: Wechsel im Vorstandsvorsitz - Shervin J. Korangy folgt auf Helen Giza | EQS-Ad-hoc: Fresenius Medical Care AG / Schlagwort(e): Personalentscheidungen / Vorstand
Fresenius Medical Care AG: Wechsel im Vorstandsvorsitz - Shervin J. Korangy folgt auf Helen... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 31,180 | -2,01 % | 200-Tage-Linie hält: Goldman verpasst Zeiss Meditec einen Dämpfer | Goldman Sachs stuft Carl Zeiss Meditec auf "Sell" ab und senkt das Kursziel auf 23 Euro. Zwischenzeitlich verlor das Papier gut sieben Prozent, fing sich dann aber knapp über der 200-Tage-Linie. Die... ► Artikel lesen | |
| ECKERT & ZIEGLER | 12,250 | +0,41 % | Eckert & Ziegler steigt - Berenberg sieht mehr Potenzial | ||
| UNITEDHEALTH | 330,20 | -1,67 % | UnitedHealthcare Unveils FY27 Medicare Advantage Plans | MINNETONKA (dpa-AFX) - Health care and well-being major UnitedHealth Group Inc. (UNH) Thursday introduced its 2027 Medicare Advantage plans, focused on affordability, simplicity and a more connected... ► Artikel lesen | |
| HIMS & HERS HEALTH | 25,340 | -4,09 % | Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership | Kultar Garcha, MD, joins as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, is named Chief Medical Officer of Hims Australia, guiding clinical strategy... ► Artikel lesen | |
| BICO GROUP | 1,934 | -0,51 % | BICO Group AB: BICO Completes Integration of Cellenion into SCIENION, Strengthening Precision Biotech Platform | BICO Group AB (publ) today announces the completion of the integration of Cellenion into SCIENION, bringing the businesses, technologies, and teams together under a single organization and brand.
This... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,011 | -100,00 % | NuGen Medical Devices Inc.: NuGen Announces Loan Agreement with Sol-Millennium Medical HK Limited | Toronto, Ontario--(Newsfile Corp. - September 21, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is pleased to announce the entering into of a loan agreement (the "Loan Agreement")... ► Artikel lesen | |
| SPINEWAY | 0,103 | 0,00 % | Spineway: H1 2026 results | H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements - UnauditedH1... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| UNIDOC HEALTH | 0,040 | -27,44 % | XFRA L7T: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VERU | 2,445 | -0,61 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| VIROMED MEDICAL | 5,700 | 0,00 % | EQS-DD: Viromed Medical AG: Heike Perbandt, Verkauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
07.10.2026 / 18:05... ► Artikel lesen | |
| BONESUPPORT | 20,380 | +2,62 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q2 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2026.
"Strong growth and improved operating... ► Artikel lesen | |
| CLARIANE | 3,200 | 0,00 % | Clariane: Signing of a new €700 million syndicated revolving credit facility maturing 2031 | 21 September 2026 Signing of a new €700 million revolving credit facility maturing in 2031 Paris, 21 September 2026: following the success of its €500 million senior bonds offering completed on 8 September... ► Artikel lesen | |
| SENSEONICS | 8,250 | +0,61 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen |
ACARIX AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (-0,85 %) liegt der Kurs bei 0,012 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACARIX AB finden Sie auf Wallstreet Online.